These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 19335744)
1. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade. Langleben D; Cacoub P Eur J Clin Invest; 2009 Jun; 39 Suppl 2():27-31. PubMed ID: 19335744 [TBL] [Abstract][Full Text] [Related]
2. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. Barst RJ; Langleben D; Badesch D; Frost A; Lawrence EC; Shapiro S; Naeije R; Galie N; J Am Coll Cardiol; 2006 May; 47(10):2049-56. PubMed ID: 16697324 [TBL] [Abstract][Full Text] [Related]
3. STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials. Langleben D; Brock T; Dixon R; Barst R; J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S80-4. PubMed ID: 15838366 [TBL] [Abstract][Full Text] [Related]
13. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma. Kabunga P; Coghlan G Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488 [TBL] [Abstract][Full Text] [Related]
14. Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension. Opitz CF; Ewert R Eur J Clin Invest; 2006 Sep; 36 Suppl 3():1-9. PubMed ID: 16919004 [TBL] [Abstract][Full Text] [Related]
15. [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008]. Cacoub P; Amoura Z; Langleben D Rev Med Interne; 2008 Apr; 29(4):283-9. PubMed ID: 18243424 [TBL] [Abstract][Full Text] [Related]
16. Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension. Barst RJ Expert Opin Pharmacother; 2007 Jan; 8(1):95-109. PubMed ID: 17163810 [TBL] [Abstract][Full Text] [Related]